Bioxcel therapeutics reports positive topline exploratory efficacy data from serenity at-home pivotal phase 3 safety trial for agitation associated with bipolar disorders or schizophrenia

Bxcl501 demonstrated a significant mean reduction in mcgi-s score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p
BTAI Ratings Summary
BTAI Quant Ranking